Ajanta Pharma Ltd. - Research Center
532331 AJANTPHARM Group (A) BSE data
Add to watchlist
| Results | |
| Statement |
Balance sheet
|
| More |
Balance sheet
(Rs crore)
| Mar ' 24 | Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | |
|---|---|---|---|---|---|
| Sources of funds | |||||
| Owner's fund | |||||
| Equity share capital | 25.27 | 25.27 | 17.17 | 17.39 | 17.54 |
| Share application money | 5.65 | 0.34 | - | - | 0.47 |
| Preference share capital | - | - | - | - | - |
| Reserves & surplus | 3,382.65 | 3,220.84 | 3,152.01 | 2,867.59 | 2,443.29 |
| Loan funds | |||||
| Secured loans | - | - | - | - | - |
| Unsecured loans | - | - | - | - | - |
| Total | 3,413.57 | 3,246.45 | 3,169.18 | 2,884.98 | 2,461.30 |
| Uses of funds | |||||
| Fixed assets | |||||
| Gross block | 2,309.13 | 2,213.88 | 2,113.52 | 2,048.20 | 1,900.81 |
| Less : revaluation reserve | - | - | - | - | - |
| Less : accumulated depreciation | 844.24 | 729.87 | 621.20 | 529.41 | 451.49 |
| Net block | 1,464.89 | 1,484.01 | 1,492.32 | 1,518.79 | 1,449.32 |
| Capital work-in-progress | 256.45 | 209.47 | 152.86 | 108.19 | 131.06 |
| Investments | 367.14 | 553.26 | 164.85 | 156.88 | 85.77 |
| Net current assets | |||||
| Current assets, loans & advances | 2,128.96 | 2,058.05 | 1,970.46 | 1,748.20 | 1,383.00 |
| Less : current liabilities & provisions | 803.87 | 1,058.34 | 611.31 | 647.08 | 587.85 |
| Total net current assets | 1,325.09 | 999.71 | 1,359.15 | 1,101.12 | 795.15 |
| Miscellaneous expenses not written | - | - | - | - | - |
| Total | 3,413.57 | 3,246.45 | 3,169.18 | 2,884.98 | 2,461.30 |
| Notes: | |||||
| Book value of unquoted investments | 67.99 | 167.20 | 42.99 | 17.89 | 70.43 |
| Market value of quoted investments | 299.15 | 386.06 | 121.86 | 138.99 | 15.34 |
| Contingent liabilities | 161.39 | 91.52 | 76.44 | 168.98 | 182.41 |
| Number of equity sharesoutstanding (Lacs) | 1259.16 | 1259.15 | 854.16 | 865.32 | 872.61 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis